RxSight (NASDAQ:RXST) Downgraded by UBS Group to Neutral
UBS Group cut shares of RxSight (NASDAQ:RXST – Free Report) from a buy rating to a neutral rating in a research report report published on Wednesday, MarketBeat.com reports. UBS Group currently has $16.00 price target on the stock, down from their prior price target of $45.00. RXST has been the subject of a number of […]
UBS Group cut shares of RxSight (NASDAQ:RXST – Free Report) from a buy rating to a neutral rating in a research report report published on Wednesday, MarketBeat.com reports. UBS Group currently has $16.00 price target on the stock, down from their prior price target of $45.00. RXST has been the subject of a number of […]